CNBC reports that shares of Gilead are taking a beating after the biotech firm said that some patients treated with its Hepatitis C drug experienced a relapse. Even so, Mark Schoenebaum, an analyst with ISI Group, maintains a "buy" rating on Gilead. Among other things, Mr. Schoenebaum stated that the best approach to treating Hepatitis C may not be with Gilead's drug or a drug from a competitor, but rather a cocktail of Gilead's drug in combination with drugs made by other companies. This approach would be similar to that used to treat AIDS patients. To see a videos of the Gilead news, click the links below:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.